Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (36) ADC Linker (2) Antibody-Drug Conjugates (ADCs) (32) ADAMTS (1) ADC Cytotoxin (2) Adenosine Receptor (1) Adenylate Cyclase (2) Akt (2) ALCAM/CD166 (1) Amino Acid Derivatives (1) Amyloid-β (13) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (2) ANGPTL (1) Antibiotic (3) Antifolate (3) Apolipoprotein (1) Apoptosis (31) Autophagy (1) Bacterial (12) Biochemical Assay Reagents (11) c-Fms (10) c-Kit (4) c-Met/HGFR (7) C-type Lectin-like Receptors (CTLRs) (3) Cadherin (1) Carbonic Anhydrase (1) Caspase (3) CCR (7) CD19 (10) CD2 (1) CD20 (13) CD22 (6) CD276/B7-H3 (4) CD28 (9) CD3 (14) CD38 (9) CD47 (5) CD6 (1) CD73 (5) CD74 (2) CDK (1) CGRP Receptor (4) Cholecystokinin Receptor (1) Claudin (4) CMV (1) Complement System (17) CTLA-4 (13) CX3CR1 (2) CXCR (5) Dan family (2) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (2) Drug-Linker Conjugates for ADC (5) EGFR (53) Endothelin Receptor (1) ERK (1) Factor VIII (1) Factor Xa (5) Factor XI (1) FAP (1) Fc Receptor (FcR) (6) FGFR (6) Filovirus (6) FLT3 (2) Fungal (1) Galectin (1) Gap Junction Protein (2) GCGR (2) GLP Receptor (1) Glucosylceramide Synthase (GCS) (1) Glutaminase (1) Glycoprotein VI (2) Guanylate Cyclase (2) HBV (3) HCV (1) HDAC (1) HIV (7) HMG Family (2) HSV (1) IFNAR (5) IGF-1R (12) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (4) Insulin Receptor (2) Integrin (19) Interleukin Related (104) Kallikrein (1) Keap1-Nrf2 (2) LAG-3 (8) LDLR (1) LOX-1 (1) LPL Receptor (1) Macrophage migration inhibitory factor (MIF) (1) MDM-2/p53 (1) Melanocortin Receptor (1) MHC (1) Microtubule/Tubulin (14) MMP (2) Monoamine Oxidase (1) mTOR (1) Mucin (8) nAChR (1) NAMPT (2) Nectin-4 (2) Neurotensin Receptor (1) NF-κB (9) NOD-like Receptor (NLR) (2) Notch (5) NTPDase (1) Orexin Receptor (OX Receptor) (3) P-selectin (2) PARP (1) PCSK9 (7) PD-1/PD-L1 (63) PDGFR (3) PERK (1) Phosphatase (1) PSMA (2) RABV (5) Radionuclide-Drug Conjugates (RDCs) (10) RANKL/RANK (2) Ras (1) RET (1) ROR (1) RSV (5) SARS-CoV (40) Ser/Thr Kinase (1) Ser/Thr Protease (2) SLC39 (Zinc Transporter) (1) Small Interfering RNA (siRNA) (1) STAT (2) Survivin (1) TAM Receptor (1) Tau Protein (5) TGF-beta/Smad (13) TGF-β Receptor (4) Thrombin (3) Tie (3) Tim3 (2) Tissue Factor Pathway Inhibitor (TFPI) (2) TNF Receptor (73) Toll-like Receptor (TLR) (7) Topoisomerase (3) Transferrin Receptor (1) Transmembrane Glycoprotein (38) Transthyretin (TTR) (2) TREM receptor (3) Trk Receptor (6) TROP2 (1) TSH Receptor (2) Tyrosinase (2) VAP-1 (2) VEGFR (15) Virus Protease (1) VISTA (1) Wnt (4) α-synuclein (2)
By Research Areas:	Cancer (474) Cardiovascular Disease (37) Endocrinology (7) Infection (84) Inflammation/Immunology (394) Metabolic Disease (33) Neurological Disease (44)

By Targets:

ADC Antibody (36)

ADC Linker (2)

Antibody-Drug Conjugates (ADCs) (32)

ADAMTS (1)

ADC Cytotoxin (2)

Adenosine Receptor (1)

Adenylate Cyclase (2)

Akt (2)

ALCAM/CD166 (1)

Amino Acid Derivatives (1)

Amyloid-β (13)

Anaplastic lymphoma kinase (ALK) (1)

Angiotensin-converting Enzyme (ACE) (2)

ANGPTL (1)

Antibiotic (3)

Antifolate (3)

Apolipoprotein (1)

Apoptosis (31)

Autophagy (1)

Bacterial (12)

Biochemical Assay Reagents (11)

c-Fms (10)

c-Kit (4)

c-Met/HGFR (7)

C-type Lectin-like Receptors (CTLRs) (3)

Cadherin (1)

Carbonic Anhydrase (1)

Caspase (3)

CCR (7)

CD19 (10)

CD2 (1)

CD20 (13)

CD22 (6)

CD276/B7-H3 (4)

CD28 (9)

CD3 (14)

CD38 (9)

CD47 (5)

CD6 (1)

CD73 (5)

CD74 (2)

CDK (1)

CGRP Receptor (4)

Cholecystokinin Receptor (1)

Claudin (4)

CMV (1)

Complement System (17)

CTLA-4 (13)

CX3CR1 (2)

CXCR (5)

Dan family (2)

Dipeptidyl Peptidase (1)

DNA/RNA Synthesis (2)

Drug-Linker Conjugates for ADC (5)

EGFR (53)

Endothelin Receptor (1)

ERK (1)

Factor VIII (1)

Factor Xa (5)

Factor XI (1)

FAP (1)

Fc Receptor (FcR) (6)

FGFR (6)

Filovirus (6)

FLT3 (2)

Fungal (1)

Galectin (1)

Gap Junction Protein (2)

GCGR (2)

GLP Receptor (1)

Glucosylceramide Synthase (GCS) (1)

Glutaminase (1)

Glycoprotein VI (2)

Guanylate Cyclase (2)

HBV (3)

HCV (1)

HDAC (1)

HIV (7)

HMG Family (2)

HSV (1)

IFNAR (5)

IGF-1R (12)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Influenza Virus (4)

Insulin Receptor (2)

Integrin (19)

Interleukin Related (104)

Kallikrein (1)

Keap1-Nrf2 (2)

LAG-3 (8)

LDLR (1)

LOX-1 (1)

LPL Receptor (1)

Macrophage migration inhibitory factor (MIF) (1)

MDM-2/p53 (1)

Melanocortin Receptor (1)

MHC (1)

Microtubule/Tubulin (14)

MMP (2)

Monoamine Oxidase (1)

mTOR (1)

Mucin (8)

nAChR (1)

NAMPT (2)

Nectin-4 (2)

Neurotensin Receptor (1)

NF-κB (9)

NOD-like Receptor (NLR) (2)

Notch (5)

NTPDase (1)

Orexin Receptor (OX Receptor) (3)

P-selectin (2)

PARP (1)

PCSK9 (7)

PD-1/PD-L1 (63)

PDGFR (3)

PERK (1)

Phosphatase (1)

PSMA (2)

RABV (5)

Radionuclide-Drug Conjugates (RDCs) (10)

RANKL/RANK (2)

Ras (1)

RET (1)

ROR (1)

RSV (5)

SARS-CoV (40)

Ser/Thr Kinase (1)

Ser/Thr Protease (2)

SLC39 (Zinc Transporter) (1)

Small Interfering RNA (siRNA) (1)

STAT (2)

Survivin (1)

TAM Receptor (1)

Tau Protein (5)

TGF-beta/Smad (13)

TGF-β Receptor (4)

Thrombin (3)

Tie (3)

Tim3 (2)

Tissue Factor Pathway Inhibitor (TFPI) (2)

TNF Receptor (73)

Toll-like Receptor (TLR) (7)

Topoisomerase (3)

Transferrin Receptor (1)

Transmembrane Glycoprotein (38)

Transthyretin (TTR) (2)

TREM receptor (3)

Trk Receptor (6)

TROP2 (1)

TSH Receptor (2)

Tyrosinase (2)

VAP-1 (2)

VEGFR (15)

Virus Protease (1)

VISTA (1)

Wnt (4)

α-synuclein (2)

By Research Areas:

Cancer (474)

Cardiovascular Disease (37)

Endocrinology (7)

Infection (84)

Inflammation/Immunology (394)

Metabolic Disease (33)

Neurological Disease (44)

850

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

894

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99232

Indusatumab 5F9 monoclonal antibody	Guanylate Cyclase	Cancer
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .

HY-P99784

Porgaviximab	Filovirus	Infection
Porgaviximab is a monoclonal antibody that can be used Ebola infection research .

HY-P99271

Tisotumab Anti-Human F3 Recombinant antibody	ADC Antibody	Cancer
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant antibody	EGFR	Cancer
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .

HY-P99509

Zelminemab AMG-301	Adenylate Cyclase	Neurological Disease
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor .

HY-P99295

Imgatuzumab RG 7160; RO 5083945; Anti-EGFR Recombinant antibody	EGFR	Cancer
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .

HY-P99409

Oregovomab Alt-2 monoclonal antibody	Transmembrane Glycoprotein	Cancer
Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells .

HY-P99825

Relfovetmab	TNF Receptor	Neurological Disease Inflammation/Immunology
Relfovetmab is an anti-NGF monoclonal antibody (mAb) .

HY-P99251

Lodelcizumab	PCSK9	Others
Lodelcizumab is a **monoclonal antibody targeting PCSK9**. Lodelcizumab can be used for the research of hypercholesterolemia .

HY-P99808

Pulocimab	VEGFR	Cancer
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .

HY-P99702

Levilimab BCD-089	Interleukin Related	Inflammation/Immunology
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-P99850

Depemokimab GSK-3511294	Interleukin Related	Inflammation/Immunology
Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma .

HY-P990079

Renvistobart	CD28	Inflammation/Immunology
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiens monoclonal antibody .

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an *anti-PD-L1* recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .

HY-157190

Fenhexamid-butyric acid	Biochemical Assay Reagents	Inflammation/Immunology
Fenhexamid-butyric acid (Compound FHo) is a hapten designed based on fenhexamid, which can produce monoclonal antibodies with an IC₅₀ value of 0.66-0.93 nM .

HY-P9969

Matuzumab EMD 72000	EGFR	Cancer
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

HY-P99616

Felzartamab MOR-202	CD38	Cancer
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .

HY-P99535

Upanovimab SCTA01	SARS-CoV	Cancer
Upanovimab (SCTA01) is a monoclonal antibody that targets the SARS-CoV-2 S protein .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99855

Divozilimab BCD-132	CD20	Inflammation/Immunology
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .

HY-P99779

Plonmarlimab TJ003234; TJM2	c-Fms SARS-CoV	Infection Inflammation/Immunology
Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .

HY-P99760

Nurulimab BCD-145	CTLA-4	Cancer
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .

HY-P99324

Tomuzotuximab Anti-Human EGFR Recombinant antibody	EGFR Apoptosis	Cancer
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .

HY-156035

Bz-DTPA	Biochemical Assay Reagents	Inflammation/Immunology
Bz-DTPA is a bifunctional chelator. Bz-DTPA can be used for preparing immunoconjugate of monoclonal antibody 2G3 labeled with indium-111 .

HY-P99329

Vadastuximab Anti-Human CD33 Recombinant antibody	Transmembrane Glycoprotein	Cancer
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .

HY-P99414

Prezalumab AMG 557	CD28	Inflammation/Immunology
Prezalumab (AMG 557) is a monoclonal antibody targeting ICOSL that has synergistic anti-inflammatory activity with CD28 antibody inhibitors .

HY-P9922

Olaratumab IMC-3G3; LY3012207	PDGFR	Cancer
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .

HY-P99447

Atidortoxumab	Bacterial	Infection
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P99820

Ranevetmab NV-01	TNF Receptor	Inflammation/Immunology
Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .

HY-P9980A

Belantamab (FUT-8 KO)	ADC Antibody TNF Receptor	Cancer
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .

HY-P99628

Futuximab	EGFR	Cancer
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .

HY-P99380

Zanidatamab 1 Publications Verification ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P99246

Bermekimab MABp1	Interleukin Related	Inflammation/Immunology Cancer
Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation .

HY-P99893

Rozibafusp alfa AMG-570	CD28 TNF Receptor	Others
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-P9938

Erenumab	CGRP Receptor	Others
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .

HY-147407

Imbotolimod	EGFR	Cancer
Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonal antibody with *anti-ERBB2* and antineoplastic activity. Imbotolimod is a derivative of telratolimod .

HY-P990059

Puxitatug	CD276/B7-H3	Cancer
Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .

HY-P99695

Lerdelimumab CAT-152	TGF-beta/Smad	Neurological Disease
Lerdelimumab (CAT-152) is an IgG4 human *anti-TGF-β2* recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .

HY-P99269

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P991147

Ledostomig	PD-1/PD-L1	Cancer
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .

HY-P99310

Perakizumab RG4934	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .

HY-P9962

Efungumab	Fungal	Infection
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-D1710

Anti-α-Tubulin Antibody, AF555 conjugate	Microtubule/Tubulin	Others
Anti-α-Tubulin Antibody, AF555 conjugate is a conjugate of mouse anti-α-tubulin monoclonal antibody and the red fluorescent dye Alexa Fluor 555. Anti-α-Tubulin Antibody, AF555 conjugate can be used for the detection of tubulin (Ex/Em: 554/567 nm) .

HY-P99372

Lorvotuzumab Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)	ADC Antibody	Cancer
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .

Cat. No.	Product Name

HY-L080

Targeted Therapy Drug Library

106 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

HY-L031

Small Molecule Immuno-Oncology Compound Library

631 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 631 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Type

HY-154818

Bovine Serum Albumin, Acetylated

Ac-BSA

Native Proteins

Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6

LPS, from Escherichia coli (O26:B6)

Carbohydrates

Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A), and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be blocked by PD149163 (HY-123434) .

Cat. No.	Product Name	Target	Research Area

HY-P3149B

LEESGGGLVQPGGSMK acetate	TNF Receptor	Inflammation/Immunology
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .

HY-P3203A

DSTYSLSSTLTLSK TFA	TNF Receptor	Inflammation/Immunology
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

HY-P10544

Humanized anti-tac (HAT) binding peptide	Interleukin Related	Others
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .

HY-P4025

ELDKWA	HIV	Others
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .

HY-P3893

PSTAIR	CDK	Metabolic Disease
PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control .

HY-P3149

LEESGGGLVQPGGSMK	TNF Receptor	Inflammation/Immunology
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .

HY-P3203

DSTYSLSSTLTLSK	Biochemical Assay Reagents	Inflammation/Immunology
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

HY-P3149A

LEESGGGLVQPGGSMK TFA	TNF Receptor	Inflammation/Immunology
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .

HY-P4810

Polyphemusin II-Derived Peptide T140	CXCR	Infection
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

Cat. No.	Product Name

HY-K0213

Protein A Agarose 1 Publications Verification
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.

HY-K0215

Protein L Agarose
MCE Protein L Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein L, effectively purifies mammalian monoclonal and polyclonal antibodies which have kappa light chain.

HY-K0214

Protein G Agarose 2 Publications Verification
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.